Herceptin (Trastuzumab)
Today, we're using lessons learned from the HER2 story to really chase a number of other cancers, including some of the most difficult cancers to treat like pancreatic cancer, ovarian cancer, lung cancer, and colorectal cancer, just to name a few - Dennis Slamon MD PhD, co-inventor Herceptin

image by: HWN
HWN Suggests
The Miracle of Herceptin for Breast Cancer
Thinking about Herceptin is a good way to consider the advances in breast cancer research and treatment. Many other drugs have been approved by the FDA since 2010, but I can’t think of one that has had the positive impact of this drug. Every now and then there is something revolutionary in cancer care; another example would be Gleevec for treatment of certain kinds of leukemia and gastrointestinal stromal tumor (GIST). Much more often, a drug becomes available that certainly helps, but takes us small steps forward. The common pace of research is slow step by slow step, each discovery building on those that have come before. It is easy to be frustrated by this trajectory and to wish for more…
Featured
Low-cost breast cancer drug 'could save lives in low-income countries'
World Health Organization approved cheap version of ‘essential medicine’ Herceptin.
Articles of Interest
A Brief History Of Herceptin® and the Her2 Cancer Gene
If there was one hero in the Her2-Herceptin story, it was Dr. Dennis Slamon, the current chairman of medical oncology at UCLA. It was through the efforts of Dr. Slamon that Genentech funded research leading to the development of Herceptin. His struggles to develop and test Herceptin were ultimately depicted in a Lifetime movie named Living Proof. It is now 2020, and despite all of the advances of the last decade, we have just arrived at the beginning. There are now at least six drugs that inhibit the Her2 gene. There are also chemotherapy drugs that have been chemically attached to Herceptin, along with similar targeted drugs that we should see in clinical use in the very near future. Again, this is just the beginning.
A Novel Drug, A Protest, And The Fight To Prevent Breast Cancer Deaths
On December 6, 1994, outside of the South San Francisco headquarters of a biotechnology company called Genentech, a group of protestors shouted, honked, waved signs, and laid out on the street. They were pleading for “access - not excuses” when it came to Genentech’s promising new treatment for metastatic breast cancer: a drug called trastuzumab, also known as Herceptin®. Now, more than 90% of women with HER2+ breast cancer are alive five years after their diagnosis. In the almost 30-years since the protests at the Genentech headquarters, HER2+ breast cancer treatments that include Herceptin® - such as chemotherapy with the addition of Herceptin® or Herceptin® by itself - have shown positive results.
Good News on Early Breast Cancer: Herceptin Treatment Can Be Shortened
A large new study that followed thousands of women with early-stage breast cancer for a median of more than five years has found that those treated with Herceptin for only six months did just as well as those who got it for a year — and they suffered fewer side effects.
Herceptin will work wonders, not miracles
One very intelligent breast cancer sufferer, Lisa Jardine, appeared on Radio 4 on Sunday to argue that "for women like myself, the new drug seems to promise a smallish reduction of an already lowish chance" of the disease recurring. She is absolutely right.
Herceptin—a targeted antibody therapy for breast cancer
The 2019 Lasker~DeBakey Clinical Medical Research Award honors three scientists—H. Michael Shepard, Dennis J. Slamon, and Axel Ullrich —who invented Herceptin, the first monoclonal antibody that blocks a cancer-causing protein, and developed it into a life-saving therapy for women with breast cancer. The innovation reduces the risk of recurrence and extends survival time for patients with metastatic as well as early-stage disease.
Resources
25 years of Herceptin: A groundbreaking advancement in breast cancer treatment
The rationale for developing Herceptin and all the things that have come after it in terms of this class of targeted therapy was relatively simple. It was an approach that was based on trying to change what we were doing in cancer medicine, which was throwing in a bomb and hoping they would kill more bad cells than good cells. Instead, we wanted to try and study the cancer cell at a molecular level and find out what was broken, identify what was broken and find out if we could target that specifically. The hope would be if we could target that specifically, we'd come up with something that was hopefully more effective and safer because normal cells wouldn't have what was broken, only the cancer cells. So that was really the rationale behind looking for things that might be broken and unique to cancer cells.
Herceptin
Herceptin is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes.

